Llwytho...
Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette–Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer
A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette–Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion(®...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Med Oncol |
|---|---|
| Prif Awduron: | , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Springer US
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5581817/ https://ncbi.nlm.nih.gov/pubmed/28866819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-017-1033-z |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|